natgillin/translations-raw huggingface dataset:
In order to minimise the potential of developing postural hypotension in patients receiving alpha-blocker treatment, patients should be stabilised on alpha-blocker therapy prior to initiating sildenafil treatment. 
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije kod bolesnika koji dobivaju terapiju alfa-blokatorima, bolesnici moraju biti stabilizirani uz terapiju alfa blokatorima prije početka liječenja sildenafilom.
Manufacturer Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Germany 
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Njemačka
What Sildenafil ratiopharm is and what it is used for 
Što je Sildenafil ratiopharm i za što se koristi
Therefore, tell your doctor if you are taking any of the following medicines: - ritonavir or saquinavir (medicines for the treatment of HIV infections); - ketoconazole or itraconazole (medicines for the treatment of fungal infections); - erythromycin (an antibiotic); - cimetidine (medicine for the treatment of heartburn and peptic ulcers); 
Stoga svog liječnika morate obavijestiti ako uzimate neki od sljedećih lijekova: ritonavir ili sakvinavir (lijekovi za liječenje HIV infekcija); ketokonazol ili itrakonazol (lijekovi za liječenje gljivičnih infekcija); eritromicin (antibiotik); cimetidin (lijek za liječenje žgaravice i čira na želucu); alfa-blokatore (skupina lijekova za liječenje povišenog krvnog tlaka ili povećane prostate [benigne hiperplazije prostate]).
Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3). 
Istovremena primjena riociguata s inhibitorima PDE5, uključujući sildenafil, je kontraindicirana (vidjeti dio 4.3).
The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied. 
Istodobna primjena s drugim inhibitorima PDE5 ili drugim oblicima liječenja erektilne disfunkcije Sigurnost i djelotvornost kombinacija sildenafila s drugim inhibitorima PDE5, s drugim terapijama za plućnu arterijsku hipertenziju (PAH) koje sadrže sildenafil ili s drugim oblicima liječenja erektilne disfunkcije nije ispitana.
- if you have a severe heart problem. 
- ako imate teške probleme sa srcem.
Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). 
Metabolizam sildenafila uglavnom je posredovan citokromom P450 (CYP) izoformama 3A4 (glavni put) i 2C9 (sporedni put).
Prolonged erections and priapism have been reported with sildenafil in post-marketing experience. 
Produžene erekcije i prijapizam prijavljeni su prilikom primjene sildenafila nakon stavljanja lijeka u promet.
GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription. 
NAČIN IZDAVANJA LIJEKA Lijek se izdaje na recept.
In order to minimise the potential for developing postural hypotension, patients should be haemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment. 
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije, bolesnici moraju biti hemodinamički stabilni uz liječenje alfa blokatorom prije početka liječenja sildenafilom.
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5). 
Prilikom primjene sildenafila u bolesnika koji uzimaju alfa-blokator savjetuje se oprez, jer istodobna primjena može dovesti do simptomatske hipotenzije u manjeg broja osjetljivih osoba (vidjeti dio 4.5).
Visual colour distortions**, Visual disturbance, Vision blurred 
Vizualni poremećaj percepcije boja**, poremećaji vida, zamagljeni vid
This is most likely to occur within 4 hours post sildenafil dosing. 
Do toga će najvjerojatnije doći unutar 4 sata nakon primjene sildenafila.
Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min), a 25 mg dose should be considered. 
Budući da je klirens sildenafila smanjen u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina <30 ml/min), potrebno je razmotriti primjenu doze od 25 mg.
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 
Istodobna primjena s inhibitorima PDE5, uključujući sildenafil, zajedno sa stimulatorima gvanilat ciklaze, kao što je riociguat, je kontrainidicirana i može potencijalno dovesti do simptomatske hipotenzije (vidjeti dio 4.5).
Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated. 
U skladu s njegovim poznatim učincima na put dušikovog oksida/cikličkog gvanozin monofosfata (cGMP) (vidjeti dio 5.1), ustanovljeno je da sildenafil pojačava hipotenzivne učinke nitrata te je zbog toga kontraindicirana njegova istodobna primjena s donorima dušikovog oksida (kao što je amil nitrit) ili nitratima u bilo kojem obliku.
- Seizures or fits - this occurs rarely. 
Napadaji ili konvulzije - javljaju se rijetko.
- if you are taking medicines that contain nitrates (e.g. glycerol trinitrate) or nitric oxide donors (e.g. amyl nitrite, also called “poppers”). 
- ako uzimate lijekove koji sadrže nitrate (primjerice glicerol trinitrat) ili donore dušikovih oksida (primjerice amil nitrit).
In volunteers with severe renal impairment (creatinine clearance < 30 mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88% respectively compared to age-matched volunteers with no renal impairment. 
U dobrovoljaca s teškim poremećajem bubrega (klirens kreatinina <30 ml/min), klirens sildenafila bio je snižen, što je rezultiralo srednjim porastom AUC i Cmax od 100%, odnosno 88% u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja bubrega.
Co-administration of sildenafil with ritonavir is not advised (see section 4.5). 
Istodobna primjena s ritonavirom Istodobna primjena sildenafila s ritonavirom se ne preporučuje (vidjeti dio 4.5).
- The other ingredients are: microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate, calcium hydrogen phosphate anhydrous, talc, macrogol 6000, titanium dioxide, iron oxide red. 
- Drugi sastojci su: mikrokristalična celuloza, hipromeloza, umrežena karmelozanatrij magnezijev stearat, bezvodni kalcijev hidrogenfosfat, talk, makrogol 6000, titanijev dioksid (E171), crveni željezov oksid.
- if you have a severe liver problem. 
- ako imate teške probleme s jetrom.
Taking these medicines with Sildenafil ratiopharm could seriously affect your blood pressure. 
Istovremena primjena tih lijekova i lijeka Sildenafil ratiopharm mogla bi ozbiljno sniziti krvni tlak.
Sildenafil ratiopharm is not indicated for use by women. 
Sildenafil ratiopharm nije namijenjen za primjenu u žena.
If this medicine does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse, you should tell your doctor. 
Trebate obavijestiti svog liječnika ako Vam ovaj lijek ne pomaže u postizanju erekcije ili ukoliko erekcija ne traje dovoljno dugo za dovršetak spolnog odnosa.
In a study of healthy male volunteers, co-administration of the endothelin antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. 
U ispitivanju sa zdravim muškim dobrovoljcima, istodobna primjena antagonista endotelina, bosentana (induktor CYP3A4 [umjereni], CYP2C9 i vjerojatno CYP2C19), u stanju dinamičke ravnoteže (125 mg dva puta dnevno) sa sildenafilom u stanju dinamičke ravnoteže (80 mg tri puta dnevno), rezultirala je sa 62,6%-tnim smanjenjem AUC, odnosno 55,4%-tnim smanjenjem Cmax sildenafila.
Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see section 4.3). 
U skladu s njegovim poznatim učincima na put dušikovog oksida/cikličkog gvanozin monofosfata (cGMP) (vidjeti dio 5.1), pokazalo se da sildenafil pojačava hipotenzivne učinke nitrata te je zbog toga kontraindicirana njegova istodobna primjena s donorima dušikovog oksida ili nitratima u bilo kojem obliku (vidjeti dio 4.3).
Since sildenafil clearance is reduced in patients with hepatic impairment (e.g. cirrhosis), a 25 mg dose should be considered. 
Budući da je klirens sildenafila smanjen u bolesnika s teškim oštećenjem funkcije jetre (npr. ciroza), potrebno je razmotriti primjenu doze od 25 mg.
EU/1/09/603/009 1 film-coated tablet EU/1/09/603/010 4 film-coated tablets EU/1/09/603/011 8 film-coated tablets EU/1/09/603/012 12 film-coated tablets EU/1/09/603/015 2 film-coated tablets EU/1/09/603/016 24 film-coated tablets EU/1/09/603/018 48 film-coated tablets 
EU/1/09/603/009 1 filmom obložena tableta EU/1/09/603/010 4 filmom obložene tablete EU/1/09/603/011 8 filmom obloženih tableta EU/1/09/603/012 12 filmom obloženih tableta EU/1/09/603/015 2 filmom obložene tablete EU/1/09/603/016 24 filmom obloženih tableta EU/1/09/603/018 48 filmom obloženih tableta
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). 
Kod primjene jednokratne doze od 100 mg sildenafila s eritromicinom, umjerenim CYP3A4 inhibitorom, u stanju dinamičke ravnoteže (500 mg dva puta dnevno tijekom 5 dana), uočen je 182%tni porast sustavne izloženosti sildenafilu (AUC).
Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. 
Sildenafil se uglavnom odstranjuje putem mikrosomalnih izoenzima jetre CYP3A4 (glavni put) i CYP2C9 (sporedni put).
- if you are already undergoing treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors. 
- ako već uzimate terapije za plućnu arterijsku hipertenziju (PAH) kje sadrže sildenafil ili neke druge inhibitore PDE5. - ako nemate erektilnu disfunkciju.
In this case, he/she may decide to give you a lower dose. 
Molimo o tome obavijestite svog liječnika koji Vam u tom slučaju može propisati manju dozu lijeka.
Penile haemorrhage, Priapism*, Haematospermia, Erection increased 
Penilna hemoragija, prijapizam, * hematospermija, produžena erekcija
Gastro oesophagael reflux disease, Vomiting, Abdominal pain upper, 
Gastroezofagealna refluksna bolest, povraćanje, bol u gornjem dijelu abdomena, suha usta
Lacrimation disorders***, Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual brightness, Conjunctivitis 
Poremećaj suzenja očiju***, bol u oku, fotofobija, fotopsija, hiperemija oka, osjećaj svjetline pri gledanju, konjuktivitis
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC. 
Istodobna primjena inhibitora HIV proteaze, ritonavira, koji je jaki P450 inhibitor, u stanju dinamičke ravnoteže (500 mg dva puta dnevno) sa sildenafilom (100 mg u jednoj dozi) rezultirala je 300%-tnim (4 puta) porastom Cmax sildenafila i 1000%-tnim (11 puta) porastom AUC sildenafila u plazmi.
What Sildenafil ratiopharm looks like and contents of the pack Sildenafil ratiopharm are white to off-white, oblong film-coated tablets with edge. 
Kako Sildenafil ratiopharm izgleda i sadržaj pakiranja Sildenafil ratiopharm su bijele do skoro bijele, duguljaste filmom obložene tablete s rubom.
Sildenafil ratiopharm 25 mg film-coated tablets EU/1/09/603/001 
Sildenafil ratiopharm 25 mg filmom obložene tablete EU/1/09/603/001
(≥ 1/1,000 and 
(≥1/1000 i
Rare (may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eye, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small particles or spots in your vision, seeing halos around lights, dilation of the pupil of the eye, discolouration of the white of the eye, penile bleeding, presence of blood in semen, dry nose, swelling of the inside of the nose, feeling irritable and sudden decrease or loss of hearing. 
Rijetko (mogu se javiti kod najviše 1 na 1000 osoba): nesvjestica, moždani udar, srčani udar, nepravilni otkucaji srca, privremeno smanjenje protoka krvi u određene dijelove mozga, osjećaj stezanja u grlu, gubitak osjeta u ustima, krvarenje u očnoj pozadini, dvoslike, smanjena oštrina vida, neuobičajena osjetljivost oka, oticanje oka ili vjeđe, sitne čestice ili mrlje u vidnom polju, aureole oko izvora svjetlosti, širenje zjenice oka, promjena boje bjeloočnice, krvarenje iz penisa, krv u sjemenoj tekućini, suhoća nosne sluznice, oticanje unutrašnjosti nosa, osjećaj razdražljivosti i iznenadno slabljenje ili gubitak sluha.
The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half-life of 3-5 h. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose). 
Nakon peroralne ili intravenske primjene, sildenafil se izlučuje u obliku metabolita, uglavnom stolicom (približno 80% primijenjene oralne doze) i u manjoj mjeri mokraćom (približno 13% primijenjene oralne doze).
EU/1/09/603/005 1 film-coated tablet EU/1/09/603/006 4 film-coated tablets EU/1/09/603/007 8 film-coated tablets EU/1/09/603/008 12 film-coated tablets EU/1/09/603/014 2 film-coated tablets EU/1/09/603/017 24 film-coated tablets 
EU/1/09/603/005 1 filmom obložena tableta EU/1/09/603/006 4 filmom obložene tablete EU/1/09/603/007 8 filmom obloženih tableta EU/1/09/603/008 12 filmom obloženih tableta EU/1/09/603/014 2 filmom obložene tablete EU/1/09/603/017 24 filmom obložene tablete
Sildenafil ratiopharm 100 mg film-coated tablets EU/1/09/603/009 
Sildenafil ratiopharm 100 mg filmom obložene tablete EU/1/09/603/009
What Sildenafil ratiopharm looks like and contents of the pack Sildenafil ratiopharm are white to off-white, oblong film-coated tablets with edge and score line on one side. 
Kako Sildenafil ratiopharm izgleda i sadržaj pakiranja Sildenafil ratiopharm su bijele do skoro bijele, duguljaste filmom obložene tablete s rubom i razdjelnom crtom s jedne strane.
Uncommon (may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes/red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired. 
Manje često (mogu se javiti kod najviše 1 na 100 osoba): povraćanje, kožni osip, iritacija oka, krvave oči/crvene oči, bol u očima, bljeskovi pred očima, osjećaj svjetline pri gledanju, osjetljivost na svjetlo, suzenje očiju, lupanje srca, ubrzani otkucaji srca, visoki krvni tlak, niski krvni tlak, bol u mišićima, osjećaj pospanosti, smanjeni osjet dodira, vrtoglavica, zvonjenje u ušima, suha usta, puni ili začepljeni sinusi, upala nosne sluznice (simptomi uključuju curenje iz nosa, kihanje i začepljen nos), bol u gornjem dijelu abdomena, gastroezofagealna refluksna bolest (simptomi uključuju žgaravicu), krv u mokraći, bol u rukama ili nogama, krvarenje iz nosa, osjećaj vrućine i osjećaj umora.
Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC. 
Istodobna primjena inhibitora HIV proteaze, sakvinavira, inhibitora CYP3A4, u stanju dinamičke ravnoteže (1200 mg tri puta dnevno) sa sildenafilom (100 mg u jednoj dozi) rezultirala je 140%-tnim porastom Cmax sildenafila i 210%-tnim porastom AUC sildenafila.
(≥ 1/10,000 and 
(≥1/10 000 i
You may find that this medicine takes longer to work if you take it with a heavy meal. 
Kad se ovaj lijek uzima s jelom, potrebno je malo dulje da počne djelovati.
Sildenafil ratiopharm 50 mg film-coated tablets EU/1/09/603/005 
Sildenafil ratiopharm 50 mg filmom obložene tablete EU/1/09/603/005
EU/1/09/603/001 1 film-coated tablet EU/1/09/603/002 4 film-coated tablets EU/1/09/603/003 8 film-coated tablets EU/1/09/603/004 12 film-coated tablets EU/1/09/603/013 2 film-coated tablets 
EU/1/09/603/001 1 filmom obložena tableta EU/1/09/603/002 4 filmom obložene tablete EU/1/09/603/003 8 filmom obloženih tableta EU/1/09/603/004 12 filmom obloženih tableta EU/1/09/603/013 2 filmom obložene tablete
Throat tightness, Nasal oedema, Nasal dryness 
Stezanje u grlu, nazalni edem, suhoća nosne sluznice
The mean AUC and Cmax of the N-desmethyl metabolite increased up to 126% and up to 73% respectively, 
Srednja AUC i Cmax N-dezmetil metabolita porasla je do 126% odnosno do 73%, u usporedbi s dobrovoljcima odgovarajućim po dobi, bez oštećenja bubrega.
1 film-coated tablet 2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 12 film-coated tablets 24 film-coated tablets 48 film-coated tablets 
1 filmom obložena tableta 2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 12 filmom obloženih tableta 24 filmom obloženih tableta 48 filmom obloženih tableta
What Sildenafil ratiopharm is 
Što je Sildenafil ratiopharm
Marketing Authorisation Holder ratiopharm GmbH Graf-Arco-Straße 3 
Nositelj odobrenja za stavljanje lijeka u promet ratiopharm GmbH
Sildenafil ratiopharm 25 mg film-coated tablets White to off-white, oblong film-coated tablet with edge. 
Sildenafil ratiopharm 25 mg filmom obložene tablete Bijela do skoro bijela, duguljasta filmom obložena tableta s rubom.
NAME OF THE MEDICINAL PRODUCT Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg film-coated tablets 
Sildenafil ratiopharm 25 mg filmom obložene tablete Sildenafil ratiopharm 50 mg filmom obložene tablete Sildenafil ratiopharm 100 mg filmom obložene tablete
Pharmacotherapeutic group: Urologicals; Drugs used in erectile dysfunction, ATC code: G04BE03 
Farmakoterapijska skupina: urološki preparati; lijekovi koji se primjenjuju kod erektilne disfunkcije.
- if you suffer from any of the following disorders, please tell your doctor who will check carefully whether this medicine is suitable for you: if you currently have a stomach ulcer; if you have a blood-clotting disorder (e.g. haemophilia). 
- ako patite od nekog od sljedećih poremećaja, o tome obavijestite svojeg liječnika koji će pažljivo provjeriti odgovara li Vam ovaj lijek:
No relevant adverse effects were found in reproduction studies in rats and rabbits following oral administration of sildenafil. 
Nakon peroralne primjene sildenafila u ispitivanjima reprodukcije u štakora i kunića nisu opažene značajne nuspojave.
resulted in a 49.8% increase in bosentan AUC and a 42% increase in bosentan Cmax (125 mg b.i.d. 
U zdravih muških dobrovoljaca, sildenafil je u stanju dinamičke ravnoteže (80 mg tri puta dnevno) rezultirao sa 49,8%-tnim povećanjem AUC bosentana i 42%-tnim povećanjem Cmax bosentana (125 mg dva puta dnevno).
1 film-coated tablet 2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 12 film-coated tablets 24 film-coated tablets 
1 filmom obložena tableta 2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 12 filmom obloženih tableta 24 filmom obložen tablete
1 film-coated tablet 2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 12 film-coated tablets 
1 filmom obložena tableta 2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 12 filmom obloženih tableta
NAME OF THE MARKETING AUTHORISATION HOLDER ratiopharm 
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET ratiopharm
INFORMATION IN BRAILLE Sildenafil ratiopharm 100 mg 
PODACI NA BRAILLEOVOM PISMU Sildenafil ratiopharm 100 mg
There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers (see section 4.6). 
Nakon jednokratnih oralnih doza sildenafila od 100 mg u zdravih dobrovoljaca nije bilo učinka na motilitet ili morfologiju spermija (vidjeti dio 4.6).
INFORMATION IN BRAILLE Sildenafil ratiopharm 25 mg 
PODACI NA BRAILLEOVOM PISMU Sildenafil ratiopharm 25 mg
How to take Sildenafil ratiopharm 
Kako uzimati Sildenafil ratiopharm
How to store Sildenafil ratiopharm 
Kako čuvati Sildenafil ratiopharm
What Sildenafil ratiopharm is used for 
Za što se Sildenafil ratiopharm koristi
Sildenafil ratiopharm 25 mg film-coated tablets Pack sizes of 1, 2, 4, 8, or 12 film-coated tablets. 
Sildenafil ratiopharm 25 mg filmom obložene tablete Veličine pakiranja od 1, 2, 4, 8, ili 12 filmom obloženih tableta.
Common (may affect up to 1 in 10 people): nausea, facial flushing, hot flush (symptoms include a sudden feeling of heat in your upper body), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness. 
Često (mogu se javiti kod najviše 1 na 10 osoba): mučnina, naleti crvenila u licu, navala vrućine (simptomi uključuju iznenadan osjećaj vrućine u gornjem dijelu tijela), probavne tegobe, obojeni vid, zamagljen vid, poremećaj vida, začepljenost nosa i omaglica.
INFORMATION IN BRAILLE Sildenafil ratiopharm 50 mg 
PODACI NA BRAILLEOVOM PISMU Sildenafil ratiopharm 50 mg
Sildenafil ratiopharm 50 mg film-coated tablets Pack sizes of 1, 2, 4, 8, 12 or 24 film-coated tablets. 
Sildenafil ratiopharm 50 mg filmom obložene tablete Veličine pakiranja od 1, 2, 4, 8, 12 ili 24 filmom obložene tablete.
In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility. 
Kod maksimalnih preporučenih doza, prisutna je 80 puta veća selektivnost u usporedbi s PDE1 te preko 700 puta u usporedbi s PDE2, 3, 4, 7, 8, 9, 10 i 11. Posebno, sildenafil ima preko 4000 puta veću selektivnost za PDE5 u usporedbi s PDE3, cAMP-specifičnoj izoformi fosfodiesteraze uključenoj u kontrolu kontraktilnosti srca.
Effects of sildenafil on other medicinal products In vitro studies 
Učinci sildenafila na druge lijekove
Sildenafil ratiopharm 100 mg film-coated tablets Each film-coated tablet contains sildenafil citrate equivalent to 100 mg of sildenafil. 
Sildenafil ratiopharm 100 mg filmom obložene tablete Svaka filmom obložena tableta sadrži sildenafilcitrat, što odgovara 100 mg sildenafila.
Sildenafil ratiopharm 25 mg film-coated tablets Each film-coated tablet contains sildenafil citrate equivalent to 25 mg of sildenafil. 
Sildenafil ratiopharm 25 mg filmom obložene tablete Svaka filmom obložena tableta sadrži sildenafilcitrat, što odgovara 25 mg sildenafila.
Flushing, Hot flush 
Naleti crvenila, navala vrućine
Sildenafil ratiopharm 100 mg film-coated tablets 
Sildenafil ratiopharm 100 mg filmom obložene tablete sildenafil
Sildenafil ratiopharm 25 mg film-coated tablets 
Sildenafil ratiopharm 25 mg filmom obložene tablete sildenafil